News

GSK, partner iTeos scrap development of lung cancer therapy
Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...
BioSpace3h
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 ...
GSK to buy efimosfermin for up to $2 billion
GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...
Fierce Biotech1d
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...
GSK slips Tuesday, underperforms market
GSK PLC closed 25.53% below its 52-week high of £18.24, which the company reached on May 16th.
Explore more
Is GSK plc (GSK) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?
Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against ...
GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth
GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...